Jaak Järv - Professor Emeritus, University of Tartu, Estonia

Value of the Information & Strength of the Argument

The talk provides valuable insights into the practical challenges of aza-peptide synthesis, drawing on the speaker’s personal experience. The argumentation is based on chemical principles, such as the reduced nucleophilicity of aza-nitrogen, and is supported by specific examples from literature and his own research. However, the presentation is somewhat informal and lacks quantitative data in some parts, relying on anecdotal evidence. The speaker effectively communicates the gap between theoretical ease and practical difficulty, which is a key takeaway.

Scientific Rigor, Source Quality, Title Accuracy

The speaker cites several sources, including a 1974 paper on chymotrypsin inhibitors and a textbook on peptidomimetics, but does not provide full references. He mentions a recent paper in ‘Archives’ that claims automated synthesis, but the exact citation is missing. The title is simply the speaker’s name and affiliation, which is appropriate for a conference talk but does not convey the specific topic. The content is consistent with the title, as it is a scientific presentation. No comments were provided for analysis.

The title is a simple name and affiliation, which is appropriate for a conference talk but does not convey the specific topic.

7/10

The speaker is an emeritus professor with direct research experience in the topic, providing a credible expert perspective. However, the talk is largely anecdotal and lacks detailed experimental data or citations to specific publications, limiting its verifiability.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction: the dream of pharmacologists for specific molecules, peptides as potential drugs, and the problem of stability.
• 02:00Introduction of aza-peptides: replacing alpha carbon with nitrogen to increase stability.
• 04:00Historical background: aza-peptides known since 1950s, but named later; 1974 paper on chymotrypsin inhibitor.
• 06:00Synthesis of aza-peptides: precursors from hydrazines, use of triphosgene, and standard peptide coupling.
• 08:00Literature survey: only 241 papers on aza-peptides from 1986 to 2025, with low yields reported.
• 10:00Challenges in synthesis: reduced nucleophilicity of aza-nitrogen, leading to very low yields.
• 12:00Research on galanin fragment: incorporation of aza-alanine, affinity loss, and receptor subtype selectivity.
• 14:00Funding difficulties due to misconceptions about synthesis ease.
• 16:00Recent paper on automated aza-peptide synthesis, which may revive interest.
• 18:00Q&A: clarification on FDA approval and the need to prove activity of aza-analogs.

• 1974 paper on aza-analog as chymotrypsin inhibitor — Mentioned as a key early example of aza-peptide stability and use as an inhibitor.
• Textbook on peptidomimetics in organic and medicinal chemistry — Cited for the claim that aza-peptides can be synthesized easily from hydrazines.
• Recent paper in 'Archives' on automated aza-peptide synthesis — Mentioned as a continuation of the speaker's work, claiming automated synthesis.

• Aza-peptides: a comprehensive review — The speaker's claims about stability and synthesis challenges are consistent with general knowledge in the field.

• Textbook claim of easy synthesis — The textbook suggests aza-peptides can be synthesized easily, but the speaker's experience shows very low yields, indicating a discrepancy.